Research Papers:

Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression

Yuhui Wang, Xiaotian Xu, Peng Zhao, Bei Tong, Zhifeng Wei and Yue Dai _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:23684-23699. https://doi.org/10.18632/oncotarget.8152

Metrics: PDF 1680 views  |   HTML 1467 views  |   ?  


Yuhui Wang1,*, Xiaotian Xu1,*, Peng Zhao1, Bei Tong1, Zhifeng Wei1, Yue Dai1

1Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, Nanjing 210009, China

*These authors are contributed equally to this work

Correspondence to:

Yue Dai, e-mail: yuedaicpu@hotmail.com

Zhifeng Wei, e-mail: zhifeng-wei@hotmail.com

Keywords: escin Ia, triple-negative breast cancer, metastasis, epithelial-mesenchymal transition, lysyl oxidase-like 2

Received: December 19, 2015     Accepted: March 02, 2016     Published: March 17, 2016


The saponin fraction of Aesculus chinensis Bunge fruits (SFAC) could inhibit the invasion and migration of MDA-MB-231 cells. Among which, escin Ia showed more potent inhibition of the invasion than other five main saponin constituents. It selectively reduced the expression of LOXL2 mRNA and promoted the expression of E-cadherin mRNA, and prevented the EMT process of MDA-MB-231 cells and TNF-α/TGF-β-stimulated MCF-7 cells. Moreover, it reduced the LOXL2 level in MDA-MB-231 cells but not in MCF-7 cells. When MCF-7 cells were stimulated with TNF-α/TGF-β, transfected with LOXL2 or treated with hypoxia, escin Ia down-regulated the level of LOXL2 in MCF-7 cells. Meanwhile, escin Ia suppressed the EMT process in LOXL2-transfected or hypoxia-treated MCF-7 cells. Of interest, escin Ia did not alter the level of HIF-1α in hypoxia-induced MCF-7 cells. In TNBC xenograft mice, the metastasis and EMT of MDA-MB-231 cells were suppressed by escin Ia. In conclusion, escin Ia was the main active ingredient of SFAC for the anti-TNBC metastasis activity, and its action mechanisms involved inhibition of EMT process by down-regulating LOXL2 expression.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8152